Healthcare/Biotech
|
Updated on 06 Nov 2025, 08:49 am
Reviewed By
Akshat Lakshkar | Whalesbook News Team
▶
Abbott India Limited reported robust financial results for the quarter ended September 2025, with net profit surging by 16% to ₹415.3 crore compared to ₹359 crore in the prior year's corresponding quarter. This significant profit growth was underpinned by steady operational performance. Revenue from operations climbed 7.7% to ₹1,757 crore from ₹1,633 crore a year ago. The company also demonstrated improved profitability through expanded operating margins. Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) rose by 14.5% to ₹502.6 crore, contributing to an expansion of the EBITDA margin to 28.6% from 26.9% in the September 2024 quarter. For context, the company had previously reported an 11.6% rise in net profit for the first quarter of FY26 (April-June).
Impact: This strong financial performance, characterized by healthy profit growth and margin expansion, is generally positive for investor sentiment and could lead to increased interest in the company's stock. The market may react favorably to consistent earnings growth and operational efficiency. Rating: 7/10
Explanation of Difficult Terms: EBITDA: This stands for Earnings Before Interest, Taxes, Depreciation, and Amortisation. It is a measure of a company's operating performance, indicating its profitability before accounting for financing decisions, accounting decisions, and tax environments. EBITDA Margin: This is calculated by dividing EBITDA by the total revenue and expressing it as a percentage. It shows how efficiently a company is generating profits from its core operations.
Healthcare/Biotech
Zydus Lifesciences Reports 39% Profit Growth in Q2 FY26, Plans ₹5,000 Crore Fundraising
Healthcare/Biotech
Sun Pharma's US Innovative Drug Sales Surpass Generics for First Time
Healthcare/Biotech
Abbott India Reports 16% Profit Jump on Strong Revenue and Margins
Healthcare/Biotech
Zydus Lifesciences' Beta-Thalassemia Drug Desidustat Receives USFDA Orphan Drug Designation
Healthcare/Biotech
Medi Assist Healthcare Profit Drops 61.6% Amidst Acquisition and Tech Investments
Healthcare/Biotech
Indoco Remedies Posts Improved Q2 Earnings, Stock Sees Gains
Energy
Vedanta Secures 500 MW Power Supply Pact with Tamil Nadu for Five Years
Economy
Indian Equity Markets Close Lower Amid Volatility and Profit Booking
Banking/Finance
Cholamandalam Investment Reports 20% Profit Growth in Q2FY26 Amid Rising NPAs
Economy
India Services Sector Growth Slows to 5-Month Low in October
Consumer Products
India's Consumer Sector Faces Sweeping Leadership Overhaul
Economy
India’s Richest Donate Record Rs 10,380 Crore in 2025, Education Top Priority
SEBI/Exchange
SEBI May Hike Proposed Cap on Mutual Fund Brokerage Fees After Industry Pushback
SEBI/Exchange
SEBI Chairman: Regulator Won't Intervene on IPO Valuations; Stresses Authentic ESG Commitments
Industrial Goods/Services
Epack Durables Shares Tumble Over 10% After Q2 Net Loss Widens
Industrial Goods/Services
Kiko Live Launches India's First B2B Quick-Commerce for FMCG, Slashing Delivery Times
Industrial Goods/Services
UPL Ltd. Recovers After Strong Q2 Results, Raises EBITDA Guidance
Industrial Goods/Services
Hindalco Industries Shares Tumble Nearly 7% on Novelis' Weak Results and Fire Impact